deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 3-arm NCT02993523

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy (Viale-a)

A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

Sponsor: AbbVie

Conditions Acute Myeloid Leukemia (AML)
Interventions Azacitidine Placebo Venetoclax
Updated 38 times since 2017 Last updated: Aug 1, 2025 Started: Feb 2, 2017 Primary completion: Dec 1, 2021 Completion: Jan 23, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Acute Myeloid Leukemia (AML) and is currently ongoing. AbbVie leads this study, which shows 38 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Jun 2017 · 3 months · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Mar 2018 · 59 days · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Mar 2020 · 6 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Jun 2021 · 4 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Jul 2022 · 10 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Aug 2023 · 6 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

38 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Aug 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Feb 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE3

▶ Show 33 earlier versions

  1. Sep 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE3

  2. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2021 — Jul 2022 [monthly]

    Active Not Recruiting PHASE3

  4. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  5. Feb 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE3

  6. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE3

  7. Mar 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  8. Sep 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  9. Jul 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  10. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE3

  11. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

  12. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE3

  13. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE3

  14. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE3

  15. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE3

  16. Nov 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  17. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  18. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  19. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  20. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  21. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  22. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE3

  23. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE3

  24. Jan 2018 — Mar 2018 [monthly]

    Recruiting PHASE3

  25. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE3

  26. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  27. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  28. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

  29. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  30. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

  31. Mar 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  32. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE3

  33. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
  • Genentech, Inc.
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Adelaide, Australia , Ancona, Italy , Angers, France , Ankara, Turkey (Türkiye) , Atlanta, United States , Baltimore, United States , Barcelona, Spain , Bergamo, Italy , Bergen, Norway and 140 more locations